Lyell Immunopharma (LYEL) Total Current Liabilities: 2020-2025
Historic Total Current Liabilities for Lyell Immunopharma (LYEL) over the last 5 years, with Sep 2025 value amounting to $31.9 million.
- Lyell Immunopharma's Total Current Liabilities fell 4.88% to $31.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.9 million, marking a year-over-year decrease of 4.88%. This contributed to the annual value of $53.8 million for FY2024, which is 55.82% up from last year.
- According to the latest figures from Q3 2025, Lyell Immunopharma's Total Current Liabilities is $31.9 million, which was down 13.62% from $36.9 million recorded in Q2 2025.
- Over the past 5 years, Lyell Immunopharma's Total Current Liabilities peaked at $63.7 million during Q2 2021, and registered a low of $30.8 million during Q1 2023.
- In the last 3 years, Lyell Immunopharma's Total Current Liabilities had a median value of $34.4 million in 2023 and averaged $35.9 million.
- In the last 5 years, Lyell Immunopharma's Total Current Liabilities tumbled by 31.62% in 2023 and then soared by 55.82% in 2024.
- Over the past 5 years, Lyell Immunopharma's Total Current Liabilities (Quarterly) stood at $46.7 million in 2021, then declined by 20.78% to $37.0 million in 2022, then fell by 6.78% to $34.5 million in 2023, then spiked by 55.82% to $53.8 million in 2024, then decreased by 4.88% to $31.9 million in 2025.
- Its last three reported values are $31.9 million in Q3 2025, $36.9 million for Q2 2025, and $41.3 million during Q1 2025.